ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.042,00
0,18%
S&P 500
6.049,24
0,88%
Dow Jones
44.025,81
1,24%
Euro vs US Dollar
1,04098
0,04%
Bitcoin
105.637,25
-0,50%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. AbCellera Biologics Inc (ABCL) Börsenkurse

AbCellera Biologics Inc

AbCellera Biologics Inc (ABCL)

NASDAQ
3,06
0,09
(3,03%)
Geschlossen 22 Januar 10:00PM
Verzögert um 15 Minuten
3,10
0,04
(1,31%)
Nach Börsenschluss: 1:07AM
Verzögert um 15 Minuten

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
3,10
Gebot
3,05
Fragen
3,10
Volumen
3.695.573
2,96 Tagesbereich 3,14
2,335 52-Wochen-Bereich 5,62
Marktkapitalisierung
913,463M
Handelsende
2,97
Handelsbeginn
3,00
Letzte Trade
1000
@
3.1
(formt)
Letzter Handelszeitpunkt
Finanzvolumen
US$ 11.320.458
VWAP
3,0632
Durchschnittliches Volumen (3 Mio.)
2.765.243
Ausgegebene Aktien
294.665.532
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-6,18
Gewinn pro Aktie (EPS)
-0,5
Erlöse
38,03M
Nettogewinn
-146,4M

Über AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners. AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Sektor
Medicinal Chems,botanicl Pds
Branche
Medicinal Chems,botanicl Pds
Website
www.abcellera.com
Hauptsitz
Vancouver, British Columbia, Can
Gegründet
-
AbCellera Biologics Inc is listed in the Medicinal Chems,botanicl Pds sector of the NASDAQ with ticker ABCL. The last closing price for AbCellera Biologics was US$2,97. Over the last year, AbCellera Biologics shares have traded in a share price range of US$ 2,335 to US$ 5,62.

AbCellera Biologics currently has 294.665.532 shares in issue. The market capitalisation of AbCellera Biologics is US$875,16 million. AbCellera Biologics has a price to earnings ratio (PE ratio) of -6.18.

ABCL Neueste Nachrichten

Weitere Nachrichten

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera (Nasdaq: ABCL) will announce its full year 2024 financial results on Thursday, February 27, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time...

9 Stunden vor
Business Wire

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T-cell engagers (TCE) in oncology. The expansion...

13 Januar 2025
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

03 Januar 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

03 Januar 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

03 Januar 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

03 Januar 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

05 Dezember 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

26 November 2024
Edgar (US Regulatory)

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences: Piper Sandler 36th Annual Healthcare Conference in New York, NY on...

21 November 2024
Business Wire

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera (Nasdaq: ABCL) today announced new data on its T-cell engager (TCE) platform, to be presented as a poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting at the...

07 November 2024
Business Wire
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.061.973684210533.043.12.75536729412.88343195CS
40.175.802047781572.933.4652.75532985353.0064421CS
120.248.391608391612.863.4652.527652432.91173696CS
260.13.3333333333333.4652.33522463932.80039902CS
52-2.2-41.50943396235.35.622.33518798343.30519896CS
156-6.0195-66.00690827359.119514.972.33519958906.76798964CS
260-57.9-94.91803278696171.912.335192198210.6141308CS

ABCL - Frequently Asked Questions (FAQ)

What is the current AbCellera Biologics share price?
The current share price of AbCellera Biologics is US$ 3,10
How many AbCellera Biologics shares are in issue?
AbCellera Biologics has 294.665.532 shares in issue
What is the market cap of AbCellera Biologics?
The market capitalisation of AbCellera Biologics is USD 875,16M
What is the 1 year trading range for AbCellera Biologics share price?
AbCellera Biologics has traded in the range of US$ 2,335 to US$ 5,62 during the past year
What is the PE ratio of AbCellera Biologics?
The price to earnings ratio of AbCellera Biologics is -6,18
What is the cash to sales ratio of AbCellera Biologics?
The cash to sales ratio of AbCellera Biologics is 23,8
What is the reporting currency for AbCellera Biologics?
AbCellera Biologics reports financial results in USD
What is the latest annual turnover for AbCellera Biologics?
The latest annual turnover of AbCellera Biologics is USD 38,03M
What is the latest annual profit for AbCellera Biologics?
The latest annual profit of AbCellera Biologics is USD -146,4M
What is the registered address of AbCellera Biologics?
The registered address for AbCellera Biologics is 2215 YUKON STREET, VANCOUVER, BRITISH COLUMBIA, V5Y 0A1
What is the AbCellera Biologics website address?
The website address for AbCellera Biologics is www.abcellera.com
Which industry sector does AbCellera Biologics operate in?
AbCellera Biologics operates in the MEDICINAL CHEMS,BOTANICL PDS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
ASSTAsset Entities Inc
US$ 0,8998
(93,71%)
263,47M
DWTXDogwood Therapeutics Inc
US$ 3,18
(70,05%)
24,31M
USEGUS Energy Corp
US$ 3,74
(61,21%)
107,79M
DOGZDogness International Corporation
US$ 27,62
(52,60%)
1,95M
MYNAMynaric AG
US$ 0,6697
(50,83%)
3,72M
GOEVCanoo Inc
US$ 0,3748
(-72,24%)
41,38M
SHOTWSafety Shot Inc
US$ 0,1094
(-47,40%)
18,06k
ORKTOrangeKloud Technology Inc
US$ 0,7068
(-36,89%)
7,48M
HEPAHepion Pharmaceuticals Inc
US$ 0,3219
(-31,36%)
1,66M
WNWMeiwu Technology Company Ltd
US$ 0,2681
(-27,05%)
11,02M
GCTKGlucoTrack Inc
US$ 0,1226
(44,41%)
613,28M
CRKNCrown Electrokinetics Corporation
US$ 0,1121
(-10,32%)
392,52M
ASSTAsset Entities Inc
US$ 0,8998
(93,71%)
262,98M
RIMEAlgorhythm Holdings Inc
US$ 0,034599
(-16,83%)
230,08M
RGTIRigetti Computing Inc
US$ 13,97
(42,12%)
226,81M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
ABCL
AbCellera Biologics
TG
LM9A
BNPP EASY Sustainable US...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten